Treatment of adjuvant arthritis using microencapsulated antisense NF-κB oligonucleotides

References

• Feldmann M, Andreakos E, Smith C, Bondeson J, Yoshimura S, Kiriakidis S, et al. Is NF-κB a useful therapeutic target in rheumatoid arthritis?. Ann Rheum Dis 2002; 61(Suppl II)ii13–ii18
   PubMedGoogle Scholar
• Tsao PW, Tatsuo S, Totsuka R, Murata T, Takagi T, Ohmachi Y, et al. The effect of dexamethasone on the expression of activated NF-κB in adjuvant arthritis. Clin Immunol Immunopathol 1997; 83: 173–178
   PubMedGoogle Scholar
• Barnes PJ, Karin M. Nuclear factor kappa B—a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 1997; 336: 1066–1077
   PubMed Web of Science ®Google Scholar
• Ghosh S, May MJ, Kopp EB. NF-kappa B and rel proteins: Evolutionarily conserved mediators of immune responses. Annl Rev Immunol 1998; 16: 225–260
   PubMed Web of Science ®Google Scholar
• D’Acquisto F, May MJ, Ghosh S. Inhibition of nuclear factor kappa B: An emerging theme in anti-inflammatory therapies. Molec Intervent 2002; 2: 22–32
   PubMedGoogle Scholar
• Li Q, Verna IM. NF-kappa B regulation in the immune system. Nature 2002; 2: 725–734
   Google Scholar
• Tak PP, Firestein GS. NF-kappa B: A key role in inflammatory diseases. J Clin Invest 2002; 107: 7–11
   Google Scholar
• D'Souza MJ, Jin Z, Oettinger CW. Treatment of experimental septic shock with microencapsulated antisense oligomers to NF-κB. J Interferon Cytokine Res 2005; 25: 311–320
   PubMed Web of Science ®Google Scholar
• Auphan N, DiDonato JA, Rosette C, Helmberg A, Karin M. Immunosupression by glucocorticoids: Inhibition of NF-kappa B activity through induction of I kappa B synthesis. Science 1995; 270: 286–290
   PubMed Web of Science ®Google Scholar
• Scheinman RI, Cogswell PC, Lofquist AK, Baldwin AS. Role of transcriptional activation of I kappa B alpha in mediation of immunosuppression by glucocorticoids. Science 1995; 270: 283–286
   PubMed Web of Science ®Google Scholar
• Ardite E, Panes J, Miranda M, Salas A, Eizalde JI, Sans M, et al. Effects of steroid treatment on activation of nuclear factor kappa B in patients with inflammatory bowel disease. Br J Pharmacol 1998; 124: 431–433
   PubMed Web of Science ®Google Scholar
• Khaled AR, Soares LS, Butfiloski EJ, Stekman I, Sobel ES, Schiffenbauer J. Inhibition of the p50 subunit of NF-kappa B by phosphorothioate-modified antisense oligodeoxynucleotides reduces NF-kappa B expression and immunoglobulin synthesis in murine B cells. Clin Immunol Immunopathol 1997; 83: 254–263
   PubMedGoogle Scholar
• Schlaak JF, Barreiros AP, Pettersson S, Schirmacher P, Meyer KH, Neurath MF. Antisense phosporothioate oligonucleotide to the p65 subunit of NF-kappa B abrogates fulminant septic shock induced by S. typhimurium in mice. Scand J Immunol 2002; 54: 396–403
   Google Scholar
• Akhtar S, Juliano RL. Cellular uptake and intracellular fate of antisense oligonucleotides. Trends Cell Biol 1992; 2: 139–144
   PubMedGoogle Scholar
• Lewis KJ, Irwin WJ, Akhtar S. Biodegradable poly (L-lactic acid) matrices for the sustained delivery of antisense oligonucleotides. J Contr Rel 1995; 37: 173–183
   Web of Science ®Google Scholar
• Akhtar S, Lewis KJ. Antisense oligonucleotide delivery to cultured macrophages is improved by incorporation into sustained-release biodegradable polymer microspheres. Int J Pharm 1997; 151: 57–67
   Web of Science ®Google Scholar
• Agrawal S, Temsamani J, Tang JY. Pharmacokinetics, biodistribution, and stability of phosporothioates in mice. Proc Natl Acad Sci USA 1999; 88: 7595–7599
   Google Scholar
• De Rosa G, Maiuri MC, Ungaro F, De Stefano D, Quaglia F, La Rotonda I, et al. Enhanced intracellular uptake and inhibition of NF-kappa B activation by decoy oligonucleotide released from PLGA microspheres. J Gene Med 2005; 7: 77–78
   Google Scholar
• Khan A, Benboubetra M, Sayyed PZ, Wooi K, Fox S, Beck G, et al. Sustained polymeric delivery of gene silencing antisense ODNs, siRNA, DNAzymes and Ribozymes: In vitro and in vivo studies. J Drug Target 2004; 12: 393–404
   PubMed Web of Science ®Google Scholar
• Oettinger CW, D'Souza MJ, Akhavein N, Peer GT, Taylor FB. Pro-inflammatory cytokine inhibition in the primate using microencapsulated antisense oligomers to NF-kB. J Microencapsulation 2007; 24: 337–348
   PubMed Web of Science ®Google Scholar
• Von Hoegen I, Waller C. Safety of human albumin based on spontaneously reported adverse events. Crit Care Med 2001; 29: 994–996
   PubMed Web of Science ®Google Scholar
• Vincent J-L, Navickis RJ, Wilkes MM. Morbidity in hospitalized patients receiving human albumin: A meta-analysis of randomized, controlled trials. Crit Care Med 2004; 32: 2029–2038
   PubMed Web of Science ®Google Scholar
• Ahsan F, Rivas IP, Khan MA, Torres Suarez AI. Targeting to macrophages: Role of physicochemical properties of particulate carriers—liposomes and microspheres—on the phagocytosis of microspheres. J Contr Rel 2002; 79: 29–40
   PubMed Web of Science ®Google Scholar
• Makino K, Yamamoto N, Higuchi K, Harada N, Ohshima H, Terada H. Phagocytic uptake of polystyrene microspheres by alveolar macrophages: Effects of size and surface properties of the microspheres. Coll Surf B Biointerfaces 2003; 27: 33–39
   Web of Science ®Google Scholar
• Oettinger CW, D'Souza MJ, Milton GV. Targeting macrophages with microspheres containing cytokine-neutralizing antibodies prevents lethality in gram-negative peritonitis. J Interferon Cytokine Res 1999; 19: 33–40
   PubMed Web of Science ®Google Scholar
• Oettinger CW, D'Souza MJ. Microencapsulation of tumor necrosis factor oligomers: A new approach to pro-inflammatory cytokine inhibition. J Interferon Cytokine Res 2003; 23: 533–543
   PubMed Web of Science ®Google Scholar
• D'Souza MJ, Oettinger CW, Milton GV, Tracey KJ. Prevention of lethality and suppression of pro-inflammatory cytokines in experimental septic shock by microencapsulated CNI-1493. J Interferon Cytokine Res 1999a; 19: 1125–1133
   PubMed Web of Science ®Google Scholar
• D'Souza MJ, Oettinger CW, Shah A, Tipping PG, Huang XR. Macrophage depletion by albumin microencapsulated clodronate: Attenuation of cytokine release in macrophage dependent glomerulonephritis. Drug Dev Ind Pharm 1999b; 25: 591–596
   PubMed Web of Science ®Google Scholar
• Zhaowei J, D'Souza MJ, Oettinger CW. Reversal of LPS induced endothelial cell TNF synthesis and increased permeability with microencapsulated antisense oligomers to NF-κB. J Microencapsulation 2007; 24: 596–607
   PubMed Web of Science ®Google Scholar
• Smith-Oliver T, Noel LS, Stimpson SS, Yarnall DP, Connolly KM. Elevated levels of TNF in the joints of adjuvant arthritic rats. Cytokine 1993; 5: 298–304
   PubMed Web of Science ®Google Scholar
• Szekanecz Z, Halloran MM, Volin MV, Woods JM, Strieter RM, Haines K, et al. Temporal expression of inflammatory cytokines and chemokines in rat adjuvant-induced arthritis. Arthritis Rheum 2000; 43: 1266–1277
   PubMed Web of Science ®Google Scholar
• Cooper WG, Fava RA, Gates CA, Cremer CA, Townes AS. Acceleration of collagen-induced arthritis by intra-articular injection of tumour necrosis factor or transforming growth factor-beta. Clin Exp Immunol 1992; 89: 244–250
   PubMed Web of Science ®Google Scholar
• Feige U, Hu Y, Gasser J, Campagnuolo G, Munyakazi L, Bolon B. Anti interleukin-1 and anti-tumor necrosis factor-α synergistically inhibit adjuvant arthritis in lewis rats. Cell Molec Life Sci 2000; 57: 1457–1470
   PubMed Web of Science ®Google Scholar
• Asahara H, Asanuma M, Ogawa M, Nishsibayashi S, Inoue H. High DNA binding activity of transcription factor NF-κB in synovial membranes of patients with rheumatoid arthritis. Biochem Molec Biol Int 1995; 37: 827–832
   PubMedGoogle Scholar
• Marok R, Winyard PG, Coumbe A, Kus ML, Gaffney K, Blades S, et al. Activation of the transcription factor nuclear factor-κB in human inflamed synovial tissue. Arthritis Rheum 1996; 39: 583–591
   PubMed Web of Science ®Google Scholar
• Han Z, Boyle DL, Manning AM, Firestein GS. AP-1 and NF-κB regulation in rheumatoid arthritis and murine collagen arthritis. Autoimmunity 1998; 28: 197–208
   PubMed Web of Science ®Google Scholar
• Yamasaki S, Kawakami A, Nakashima T, Nakamura H, Kamachi H, Honda S, et al. Importance of NF-κB in rheumatoid synovial tissues: In situ NF-κB expression and in vitro study using cultured synovial cells. Ann Rheum Dis 2001; 60: 678–684
   PubMedGoogle Scholar
• Benito MJ, Murphy E, Murphy EP, Van Den Berg WB, FitzGerald O, Bresnihan B. Increased synovial tissue NF-κB expression at sites adjacent to the cartilage-pannus junction in rheumatoid arthritis. Arthritis Rheum 2004; 50: 1781–1787
   PubMedGoogle Scholar
• Carlsen H, Moskaug JO. In vivo imaging of NF-κB activity. J Immunol 2002; 68: 1141–1146
   Google Scholar
• Pahl HL. Activators and target genes of Rel/NF-κB transcription factors. Oncogene 1999; 18: 6853–6866
   PubMed Web of Science ®Google Scholar
• D’Acquisto F, Ialenti A, Ianaro A, Di Vaio R, Carnuccio R. Local administration of transcription factor decoy oligonucleotides to nuclear factor-κB prevents carrageenin-induced inflammation in rat hind paw. Gene Therapy 2000; 7: 1731–1737
   PubMedGoogle Scholar
• Tomita T, Takano H, Tomita N, Morishita R, Kaneko M, Shi K, et al. Transcription factor decoy for NF-κB inhibits cytokine and adhesion molecule expressions in synovial cells derived from rheumatoid arthritis. Rheumatology 2000; 39: 749–757
   PubMed Web of Science ®Google Scholar
• Keystone EC. Tumor necrosis factor-α blockade in the treatment of rheumatoid arthritis. Rheum Dis Clin N Am 2001; 27: 427–443
   PubMed Web of Science ®Google Scholar
• Pearce GP, Chikanza IC. Targeting tumour necrosis factor in the treatment of rheumatoid arthritis. BioDrugs 2001; 15: 39–149
   Google Scholar